About Us
ADVI is a global team of technical experts, data scientists, clinicians, product innovators, and payer Advisors. Our history of successful growth for over a decade is directly attributable to our commitment to our clients, many of whom have been clients long before ADVI, most for over 15 years, interest in politics, passion for policy as a driver of access and reimbursement, and speed to address the thorniest of business issues. We bring our specific subject-matter expertise, an encyclopedic knowledge of rules and regulations, and a long history of success. We combine the advice, action, and tools of traditional consulting with the rigor and vision of experienced corporate strategists. Our unique datasets and targeted advocacy, advances innovation for leading cell, biologic, drug, and gene therapy, device and supply, molecular-diagnostics manufacturers, digital-therapy companies, trade associations, provider and patient advocacy groups and organizations, and cancer providers.
ADVI’s approach is centered on our Solution areas: State and Federal Policy; Market Access; Financial Due Diligence; Coding and Reimbursement; and Strategic Analytics and Value Evidence; and two dedicated service lines, advisory services and insights. By working cross-functionally and without walls, we deliver results for emerging biotech firms and established pharmaceutical companies, medtech (devices, digital therapeutics, and AI), precision medicine, provider groups, trade associations, private equity and venture capital. Our cross-disciplinary Solutions teams and our industry leading team of former payers, government officials and brand and market strategists support clients throughout the product lifecycle from bench to bedside, molecule to market – in corporate development, pre-commercial planning, pre- and peri-launch, and through commercial execution.
In December 2022, ADVI made the decision to bring on a strategic partner, Sheridan Capital Partners (SCP), a Chicago-based healthcare focused private equity firm. The collaboration with SCP enables ADVI to accelerate our growth by investing in key areas of our business to bring unique data-informed solutions to the market while expanding our core products and services. We are focused on the expanding in the following areas: pricing; contracting; and go-to market capabilities for our life sciences customer base; a deeper focus on data assets; health economics and outcomes research; and due diligence for capital markets. This partnership accelerates our ability to help clients with data analytics by locking in unique and proprietary datasets, products and proven business improvement methods.
This is an exciting time within the healthcare industry for our clients, and our partners. Our focus on growth and acquisition will drive meaningful and measurable impact through data-informed insights for core areas of our existing client base across cancer, vaccines, rare disease, cell and gene therapies, precision medicine, and medtech, such as brand, field (direct to payer, Medicare contractor, Medicaid and Medicaid health plan direct advocacy, training and education) , market insights, new product planning, and clinical development work. We are actively working to acquire and combine best-in-class firms in like and adjacent disciplines (i.e., market access, policy, data and analytics, HEOR, and due diligence) to ADVI in concert with our partner, SCP.
Advancing patient access, accelerating time to reimbursement, and providing winning business and strategic advice to lifescience and healthcare innovators, established companies, those that provide care on their behalf, and those that fund them.
